Therma Bright Secures Purchase Order For 1,750 Venowave W5 Units From National Distributor - DME Authority of Nashville, TN
Rhea-AI Summary
Therma Bright (TBRIF) has secured a significant purchase order for 1,750 Venowave VW5 units from DME Authority, a national distributor based in Nashville, Tennessee. The order follows successful pilot trials and a previously signed Letter of Intent (LOI) positioning DME as a 'Premier Distributor Partner'. The purchase order represents potential HCPCS code reimbursements totaling $1,434,212 USD (approximately $2,051,602 CAD).
The company has initiated production with a new manufacturing partner to meet growing demand from their national distribution network. This development comes amid a promising market outlook, with the global compression therapy market valued at $4.18 billion in 2024 and projected to reach $6.72 billion by 2033, representing a CAGR of 7.30%.
Positive
- Secured purchase order for 1,750 Venowave VW5 units worth $1.43M USD
- Established partnership with national distributor DME Authority
- New manufacturing partnership initiated to meet growing demand
- Operating in a growing market with 7.30% CAGR projection through 2033
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, TBRIF gained 16.38%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
National Distributor Eager To Begin Sales & Marketing Of Vascular Compression Therapy Solutions
Toronto, Ontario--(Newsfile Corp. - January 21, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce that it has secured a purchase order for 1,750 Venowave VW5 from national distribution partner DME Authority of Nashville, Tennessee. DME, along with their partner network, was just one of the Company's national distributors who have experienced successful pilot trials.
Last month, distribution partner DME Authority signed a Letter of Intent (LOI) for distributing the Venowave VW5 to its U.S. distribution network. This purchase order brings both companies one step closer to the outlined LOI that positions DME as a 'Premier Distributor Partner' for Therma Bright. This initial purchase order for 1750 Venowave VW5 units offers HCPCS code reimbursements that total
"It is very exciting to see our distribution program with DME come to fruition," shared Rob Fia, CEO of Therma Bright. "Our current inventory is seeing great traction, so we've begun the process with our new manufacturing partner to begin production on new inventory, which we anticipate will arrive to meet the demand of our growing national distribution network. As always, we will keep the market updated on our progress with sales and manufacturing."
The global compression therapy market was valued at
About Venowave VW5
The Venowave VW5 is a compact, battery-operated peristaltic pump designed to diminish post-op pain & swelling and enhance blood circulation while harnessing the multitude of advantages that come with increased venous blood flow by
About DME Authority, LLC
DME Authority partners with a select network of top-tier medical distributors and healthcare providers to deliver outcome-driven solutions that set new standards for patient care. By aligning with forward-thinking organizations, we bring innovative sales and distribution strategies to life, backed by comprehensive billing expertise and strategic funding programs. Our unique approach ensures our partners achieve unmatched success while transforming healthcare delivery across the U.S. Visit: www.dmeauthority.com
About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237912
FAQ
What is the value of Therma Bright's (TBRIF) recent Venowave VW5 purchase order?
How many Venowave VW5 units did DME Authority order from Therma Bright (TBRIF)?
What is the projected growth of the compression therapy market by 2033?
Who is Therma Bright's (TBRIF) new distribution partner for Venowave VW5?
